Recommendations for pharmacological management of inpatient aggression in children and adolescents
- PMID: 20376274
- PMCID: PMC2848469
Recommendations for pharmacological management of inpatient aggression in children and adolescents
Abstract
Objective. While there has been a great deal of speculation by clinical researchers over the last three decades on effective and safe methods for the pharmacological management of aggression in children and adolescents, it is only in the last decade that there have been well-designed studies available to address this issue. Medication is commonly used to control aggression in children and adolescents in inpatient units. Also, there exists a need for evidence-based guidelines for the use of these different pharmacological agents for managing pediatric aggression on inpatient units. The aims of this article are to provide a systemic review and to provide treatment guidelines based on these limited but currently available studies.Methods. The articles reviewed in this study were obtained through a PubMed search using the key words 'children,' 'adolescents,' 'aggression,' 'inpatient,' 'ziprasidone,' 'lithium,' and 'risperidone.' A total of 499 studies were generated. Only studies focusing on pharmacological management of inpatient pediatric aggression with mean duration less than six weeks and published during January 1980 to August 2009 were included. Only English articles were considered. A total of 13 studies met these criteria, which were included in the review without any further statistical analysis. Recommendations are made on this available evidenced-based literature.Results. There is some evidence for the standing use of oral lithium, haloperidol, olanzapine, and risperidone for aggression related to specific psychiatric diagnoses. Intramuscular ziprasidone and olanzapine administered as needed were found to be effective for the rapid management of moderate to severe aggression. Oral or intramuscular diphenhydramine administered as needed was found to be useful for managing mild aggression due to a placebo effect.Conclusions. Studies are available on managing aggression in children and adolescents in inpatient treatment settings but are limited. Further studies on the use of various psychotropic medications are needed in order to develop comprehensive guidelines for the safe and effective pharmacological management of child and adolescent inpatient aggression.
Keywords: adolescents; aggression; antipsychotics; behavioral; children; inpatient; management; psychiatric; ziprasidone.
Figures
Similar articles
-
The expert consensus guideline series. Treatment of behavioral emergencies 2005.J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2. doi: 10.1097/00131746-200511001-00002. J Psychiatr Pract. 2005. PMID: 16319571
-
Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents.J Child Adolesc Psychopharmacol. 2005 Apr;15(2):270-84. doi: 10.1089/cap.2005.15.270. J Child Adolesc Psychopharmacol. 2005. PMID: 15910211 Review.
-
A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.J Child Adolesc Psychopharmacol. 2006 Dec;16(6):671-7. doi: 10.1089/cap.2006.16.671. J Child Adolesc Psychopharmacol. 2006. PMID: 17201611
-
[Prescription of olanzapine in children and adolescent psychiatric patients].Encephale. 2007 Mar-Apr;33(2):188-96. doi: 10.1016/s0013-7006(07)91549-3. Encephale. 2007. PMID: 17675914 Review. French.
-
Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Trends Psychiatry Psychother. 2013;35(3):151-9. doi: 10.1590/s2237-60892013000300002. Trends Psychiatry Psychother. 2013. PMID: 25923387
Cited by
-
Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth.J Pediatr Pharmacol Ther. 2021;26(1):33-41. doi: 10.5863/1551-6776-26.1.33. Epub 2021 Jan 4. J Pediatr Pharmacol Ther. 2021. PMID: 33424498 Free PMC article.
-
Atypical antipsychotics for disruptive behaviour disorders in children and youths.Cochrane Database Syst Rev. 2017 Aug 9;8(8):CD008559. doi: 10.1002/14651858.CD008559.pub3. Cochrane Database Syst Rev. 2017. PMID: 28791693 Free PMC article.
-
Evaluation of the use of chlorpromazine for agitation in pediatric patients.Ment Health Clin. 2021 Mar 31;11(2):40-44. doi: 10.9740/mhc.2021.03.040. eCollection 2021 Mar. Ment Health Clin. 2021. PMID: 33850680 Free PMC article.
-
Updates in the Assessment and Management of Agitation.Focus (Am Psychiatr Publ). 2023 Jan;21(1):35-45. doi: 10.1176/appi.focus.20220064. Epub 2023 Jan 16. Focus (Am Psychiatr Publ). 2023. PMID: 37205032 Free PMC article.
-
Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.Can J Psychiatry. 2017 Sep;62(9):635-647. doi: 10.1177/0706743717720197. Epub 2017 Aug 2. Can J Psychiatry. 2017. PMID: 28764561 Free PMC article. Review.
References
-
- Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in children. Int Rev Psychiatry. 2008;20(2):151–157. - PubMed
-
- Vitiello B, Hill JL, Elia J, et al. P.R.N. medications in child psychiatric patients: a pilot placebo-controlled study. J Clin Psychiatry. 1991;52(12):499–501. - PubMed
-
- Vitiello B, Ricciuti AJ, Behar D. P.R.N. medications in child state hospital inpatients. J Clin Psychiatry. 1987;48(9):351–354. - PubMed
-
- Srivastava A. Limited evidence for the effectiveness of p.r.n. medications among psychiatric inpatients. J Psychiatr Pract. 2009;15(3):193–201. - PubMed
-
- Chengappa KN, Levine J, Ulrich R, et al. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry. 2000;45(9):827–832. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous